The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Live cell in vitro prognostic utilizing biophysical and molecular biomarkers for measuring local growth and metastatic potential in prostate cancer.
Ashok C. Chander
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Michael S. Manak
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Senthil K. Ramu
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Wendell R. Su
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Thiagu Meyyappan
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Brad J. Hogan
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Matt J. Whitfield
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics
Jonathan S. Varsanik
Employment or Leadership Position - Cellanyx Diagnostics
Stock Ownership - Cellanyx Diagnostics